Literature DB >> 10665852

Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL Working Group.

A Micheli1, S Francisci, V Krogh, A G Rossi, P Crosignani.   

Abstract

AIM: To present data on cancer prevalence for the areas covered by Italian cancer registries, by using a standardized set of data collection and elaboration criteria, and a single method of data analysis. SUBJECTS AND METHODS: Data on over 250,000 patients with cancer, diagnosed between 1978 and 1992, from 11 Italian cancer registries covering about 12% of the Italian population were collected, validated and analyzed according to the unified protocol of the ITAPREVAL project. The method implemented in the PREVAL computer program was used to provide prevalence estimates for the period covered by cancer registration. The total prevalence for each registry and for the pool of all registries was then estimated by correcting for incomplete observations due to the period in which the registration was not yet activated. All prevalence estimates were for 1992.
RESULTS: Prevalence figures are presented by cancer site, age, sex, years from diagnosis and registry area. For all malignancies combined, total prevalence ranged from 1,350 per 100,000 inhabitants in Ragusa to 3,650 per 100,000 inhabitants in Romagna, the ratio between these two extremes being 2.7. For the pool of the areas covered by registration cancer prevalence was 3,100 per 100,000 females and 2,250 per 100,000 males. About a third of the total female cases and about half the male cases were diagnosed in the previous five years. Among those aged over 75 years, total prevalence was higher for males than for females: 11,300 versus 8,900 per 100,000 respectively.
CONCLUSIONS: This is the first large-scale estimate of the burden of cancer in Italy. It is also one of the first studies in the world which was aimed to study cancer prevalence in detail. These data are necessary for predicting health service needs and help in the evaluation of differences in health service demand by sex, age and Italian regions.

Entities:  

Mesh:

Year:  1999        PMID: 10665852     DOI: 10.1177/030089169908500502

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  11 in total

1.  Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.

Authors:  Paolo Boscolo-Rizzo; Giancarlo Tirelli; Monica Mantovani; Vittorio Baggio; Valentina Lupato; Giacomo Spinato; Alessandro Gava; Maria Cristina Da Mosto
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-11-04       Impact factor: 2.503

2.  Late toxicity, evolving radiotherapy techniques, and quality of life in nasopharyngeal carcinoma.

Authors:  Luciana Lastrucci; Silvia Bertocci; Vittorio Bini; Simona Borghesi; Roberta De Majo; Andrea Rampini; Paola Pernici; Pietro Giovanni Gennari
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

3.  MiRNA-29c regulates cell growth and invasion by targeting CDK6 in bladder cancer.

Authors:  Xin Zhao; Junliang Li; Shengsong Huang; Xiaodong Wan; Huarong Luo; Denglong Wu
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

4.  MiR-4295 promotes cell growth in bladder cancer by targeting BTG1.

Authors:  Yong-Hao Nan; Jun Wang; Yao Wang; Peng-Hao Sun; Yu-Ping Han; Li Fan; Kai-Chen Wang; Fu-Jun Shen; Wei-Hua Wang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

5.  [Prevalence of cancer in the Guadalajara health area].

Authors:  J M Alonso Gordo; A Bárcena Marugán; D Jiménez Del Val; J J Palacios Rojo; C Royo Sánchez; J Urbina Torija
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

6.  Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population.

Authors:  Daris Ferrari; Carla Codecà; Cecilia Bertuzzi; Francesca Broggio; Francesca Crepaldi; Andrea Luciani; Irene Floriani; Mohssen Ansarin; Fausto Chiesa; Daniela Alterio; Paolo Foa
Journal:  BMC Cancer       Date:  2012-05-30       Impact factor: 4.430

7.  CHOP 5'UTR-c.279T>C and +nt30C>T variants are not associated with overweight condition or with tumors/cancer in Italians - a case-control study.

Authors:  Ramachandran Meenakshisundaram; Nunzia Piumelli; Laura Pierpaoli; Claudia Gragnoli
Journal:  J Exp Clin Cancer Res       Date:  2009-06-26

8.  Out-of-pocket costs for cancer survivors between 5 and 10 years from diagnosis: an Italian population-based study.

Authors:  Paolo Baili; Francesca Di Salvo; Francesco de Lorenzo; Francesco Maietta; Carmine Pinto; Vera Rizzotto; Massimo Vicentini; Paolo Giorgi Rossi; Rosario Tumino; Patrizia Concetta Rollo; Giovanna Tagliabue; Paolo Contiero; Pina Candela; Tiziana Scuderi; Elisabetta Iannelli; Stefano Cascinu; Fulvio Aurora; Roberto Agresti; Alberto Turco; Milena Sant; Elisabetta Meneghini; Andrea Micheli
Journal:  Support Care Cancer       Date:  2015-11-16       Impact factor: 3.359

9.  CDK4 IVS4-nt40 AA genotype and obesity-associated tumors/cancer in Italians - a case-control study.

Authors:  Ramachandran Meenakshisundaram; Claudia Gragnoli
Journal:  J Exp Clin Cancer Res       Date:  2009-03-28

10.  Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network.

Authors:  Claudia Pizzi; Grazia Arpino; Giuseppe Acampora; Nadia Aiello; Augusto DE Rosa; Immacolata Diaferia; Alessandro DI Nunzio; Giuseppe Fragna; Amedeo Franco; Maria Russo; Fulvia Sansone; Carmela Scarpati; Antonio Spinuso; Giovanni Arpino; Amalia Luce; Giuseppina Tommasielli; Michele Caraglia; Sabino DE Placido
Journal:  Mol Clin Oncol       Date:  2013-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.